The role of dietary supplements in the treatment of Primary Dysmenorrhea: Vitamin D₃ and Zinc

Papel de los suplementos alimenticios en el tratamiento de la Dismenorrea Primaria: Vitamina D₃ y Zinc

Lilian Scarlet Gerardo-Muñoz

Abstract:

Dysmenorrhea is defined as 'painful menstruation,' and two types of dysmenorrhea are known: primary, which occurs in the absence of any gynecological disease, and secondary, which is associated with underlying conditions such as endometriosis, myomatosis, among others. Primary dysmenorrhea typically occurs approximately 6 months after menarche; around 16 to 81% of women of reproductive age suffer from Primary Dysmenorrhea, of which 2 to 29% report moderate to severe intensity. The objective of this manuscript is to propose vitamin D₃ and zinc as complementary treatments to first-line analgesics to reduce the pain associated with Primary Dysmenorrhea. The treatment of Primary Dysmenorrhea focuses on pain relief; however, taking dietary supplements such as Vitamin D₃ and Zinc should be considered. These supplements inhibit the synthesis of prostaglandins, thereby improving uterine microcirculation and reducing the intensity of uterine contractions. It is important to mention that not only pharmacological treatment should be considered, but lifestyle changes should also be made that provide a maximum state of physical and emotional well-being to reduce the consumption of analgesics and control or remit the underlying pathology.

Keywords:
Dysmenorrhea, Primary Dysmenorrhea, treatment, nutritional supplement, vitamin D₃, zinc, prostaglandins.

Resumen:

La dismenorrea es definida como “menstruación dolorosa”, se conocen dos tipos de dismenorrea, la primaria que se presenta en ausencia de alguna enfermedad ginecológica y la secundaria que se asocia a alguna patología subyacente como endometriosis, miomatosis, entre otras; la dismenorrea primaria se presenta aproximadamente 6 meses después de la menarca; alrededor del 16 al 81% de mujeres en edad fértil padecen Dismenorrea Primaria, de las cuales el 2 al 29% refieren intensidad moderada-severa. El objetivo de este manuscrito es proponer como tratamiento complementario a los analgésicos de primera línea a la vitamina D₃ y el zinc para reducir el dolor asociado a la Dismenorrea Primaria. El tratamiento de la Dismenorrea Primaria se centra en el alivio del dolor, sin embargo, se deben considerar suplementos alimenticios tales como la Vitamina D₃ y el Zinc, estos suplementos inhiben la síntesis de prostaglandinas, logrando así la mejora en la microcirculación uterina y por lo tanto la intensidad de las contracciones uterinas se reduce. Es importante mencionar que no sólo se debe considerar el tratamiento farmacológico, también se deben hacer cambios en el estilo de vida que provean de un estado máximo de bienestar físico y emocional con el objetivo de reducir el consumo de analgésicos y tener un control o remisión de la patología base.

Palabras Clave:
Dismenorrea, Dismenorrea Primaria, tratamiento, suplemento alimenticio, vitamina D₃, zinc, prostaglandinas.

* Consultorio Particular, https://orcid.org/0000-0001-6396-7516, Email: scarlet.2508@gmail.com

Received: 02/03/2024, Accepted: 25/04/2024, Postprint: 10/05/2024, Published: 05/07/2024

DOI: https://doi.org/10.29057/mjmr.v12i24.12405
INTRODUCTION
Primary dysmenorrhea, commonly known as menstrual pain, is a condition that significantly affects the quality of life of millions of women worldwide. Although it is considered a benign condition, its impact on daily life can be debilitating, interfering with everyday activities, work performance, and emotional health. In recent years, there has been increasing interest in the role of nutrients and supplements in managing Primary Dysmenorrhea. Among these supplements, Vitamin D₃ and zinc have emerged as potential agents due to their anti-inflammatory, analgesic, and hormone-regulating properties.

PRIMARY DYSMENORRHEA

Definition and classification
Dysmenorrhea is known as pain during menstruation; two types of dysmenorrhea are known: Primary Dysmenorrhea (PD) and Secondary Dysmenorrhea (SD). The PD is the type that occurs in the absence of underlying pathology. It is considered the most common chronic cyclic pain in women aged 12 to 30 years and is known to decrease as a woman's age advances beyond the third decade of life. The duration of the condition ranges from 8 to 72 hours, and it is accompanied by other symptoms such as low back pain, nausea, vomiting, diarrhea, headache, and behavioral disorders, with the latter being less addressed. Additionally, symptoms such as syncope, hyperthermia, and metrorrhagia are also associated with PD and SD is associated with the presence of underlying pathologies such as endometriosis, myomatosis, adenomyosis, and pelvic inflammatory disease, among others. Its main symptom is metrorrhagia.

PD typically occurs approximately six months after the first menstruation, a time in a woman's sexual life when ovulatory menstrual cycles have been established. It is considered the most common gynecological condition in women of childbearing age.

Epidemiology
The prevalence of menstruating women suffering from PD ranges from 16% to 91%, with 2% to 29% experiencing moderate to severe intensity pain. It is estimated that in Mexico, around 90% of women who seek primary care report dysmenorrhea, of which 15% to 50% are women of childbearing age.

Risk Factors
Risk factors for PD are varied. The most common is early menarche. Several studies have shown that the earlier a woman experiences menarche, the greater the risk of developing PD and the severity of symptoms, particularly when menarche occurs before the age of 12. Parity and multiparity are associated with decreased intensity of PD. Age is associated with lower severity of symptoms for women over 30 years. A higher risk of severity is associated with the amount of menstrual flow and the duration of the menstrual phase within the cycle for women experiencing hypermenorrhea. Habits such as smoking, obesity, and a sedentary lifestyle increase the risk of developing PD. The risk factors are detailed in Table 1.

Table 1. Risk Factors for Primary Dysmenorrhea

| Individual and Family factors | Hereditary History of 1st Grade History<br>Age <30 years old |
| Factors associated with menstruation | Irregularity of the menstrual cycle<br>Early menarche<br>Hyperpolymenorrhea<br>Infertility |
| Lifestyles | Consumption of alcohol, tobacco<br>and/or other licit or illicit drugs<br>Sedentarism<br>High consumption of junk food, high levels of saturated fats<br>Obesity |
| Pathophysiological factors | Previous pathologies<br>Sexual abuse<br>Anxiety<br>Low BMI<br>Depression |

Pathophysiology
The pathophysiology of PD involves the synthesis of Prostaglandins (PG), Prostaglandin E₂ (PGE₂), and Prostaglandin E₂ alpha (PGE₂α), which cause potent vasoconstriction, ischemia, and hypoxia in the uterine muscle. They also stimulate the production of substances such as adrenaline and hormones that generate tissue damage, inflammation, and pain. These PG are derivatives of arachidonic acid metabolism by the enzyme cyclooxygenase 1 and 2 (COX-1,2). The corpus luteum regression occurs during the luteal phase of the menstrual cycle, leading to an increase in phospholipase A₂ and then to an increase in arachidonic acid, which, in turn, increases the production of PG. PG are intracellular substances that derive from long-chain polyunsaturated fatty acids. Among the nine types of PG, PGE₂ and PGE₂α are the most implicated in PD, causing potent contraction of uterine vessels while simultaneously decreasing the pain threshold of nerve endings. It is believed that leukotriene E₄ has a similar mechanism, as shown in Figure 1.

Treatment
PD treatment aims to provide pain relief. Treatment is divided into pharmacological, non-pharmacological, and surgical; currently, pharmacological treatment is considered the first option and mainly consists of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). According to the pathophysiology, PG mediates PD, and that is why NSAIDs are considered the first-line treatment. The first-line NSAIDs consist of non-selective ones.
such as naproxen, ibuprofen, mfenamic acid, flufenamic acid, acetylsalicylic acid, or the analgesic acetaminophen. For individuals at higher risk of gastrointestinal damage, it is suggested the use of celecoxib, meloxicam, or nimesulide. An alternative to pharmacological treatment could be combining Oral Contraceptives (COC).\textsuperscript{19,21-24}

![Figure 1. Pathway of Pain in Primary Dysmenorrhea.\textsuperscript{18}](image)

Non-pharmacological treatment focuses on lifestyle changes (healthy eating and regular physical activity) aimed at reducing the production of arachidonic acid.\textsuperscript{3} The placement of Transcutaneous Electrostimulators (TENS) is also considered an alternative for treating PD, as they provide rapid, effective, and long-lasting relief, besides being biologically safe. They are considered an alternative capable of replacing or being combined with NSAIDs.\textsuperscript{25}

Surgical treatment is prescribed when none of the alternatives (pharmacological and non-pharmacological) has shown relief. Among the most common are laparoscopic uterosacral nerve ablation, presacral neurectomy, intrauterine manual aspiration, and hysterectomy.\textsuperscript{5}

**PHARMACOLOGICAL ALTERNATIVES: DIETARY SUPPLEMENTS.**

A dietary supplement is a substance that helps meet nutritional needs in the face of a deficiency of essential vitamins or minerals. As established before, PD is a complex combination of somatic and psychological symptoms that occur from ovulation to the onset of menstrual bleeding or within its first three days. Supplements such as vitamin D\textsubscript{3}, zinc, magnesium, vitamin K, vitamin E, and omega-3 fatty acids, as well as supplementing the diet with fennel, dietary fiber, or olive oil complement the treatment.\textsuperscript{8,26,27} Table 2 describes the general properties of the mentioned dietary supplements.

**Vitamin D**

Vitamin D\textsubscript{3}, compared to other essential vitamins for health, is unique in its function due to the various available sources. Vitamin D\textsubscript{3} (ergocalciferol) is obtained from UV irradiation of ergosterol, a steroid present mainly in fungi. Vitamin D\textsubscript{3} or cholecalciferol is synthesized by UV irradiation of 7-dehydrocholesterol, resulting in pre-vitamin D in the skin of animals under UVB wavelengths of 290-320nm.\textsuperscript{29}

Vitamin D\textsubscript{3} is found in foods such as eggs, fatty fish, and enriched and fortified foods. The daily requirement for vitamin D\textsubscript{3}, according to age from 1 to 70 years, which includes the fertile age of women with PD (12 to 30 years old), is 15mcg (500000IU).\textsuperscript{29,30} The amount of vitamin D in plasma is determined by exposure to sunlight radiation. Sun exposure is recommended, at least 30 minutes a day, preferably before 10:00 am and after 5:00 pm.\textsuperscript{31,32} The classification levels of plasma Vitamin D are as follows:

- deficiency: <25 mmol/L;
- insufficiency: 25-75 mmol/L;
- and normal: >75 mmol/L.\textsuperscript{22}

Vitamin D\textsubscript{3} plays a very important role in calcium homeostasis. *Per se*, vitamin D\textsubscript{3} is biologically inert. It is metabolized through the hydroxylation of 25-hydroxyvitamin D\textsubscript{3} in the liver and kidney, which improves the intestinal absorption of calcium and phosphate as well as bone mineralization\textsuperscript{33} and within the process of female reproduction, receptors for this vitamin are expressed in the endometrium, ovarian tissue, fallopian tubes, decidua, and placenta. A deficiency of this vitamin increases the risk of experiencing depressive symptoms, fibromyalgia, and uterine fibroids.\textsuperscript{26,33}

A relationship between vitamin D\textsubscript{3} deficiency and insufficiency with severe and very severe dysmenorrhea, has been identified as this vitamin reduces the production of endometrial prostaglandins, thus regulating the expression of COX-1 and COX-2.\textsuperscript{31,34-36} The enzyme phospholipase A\textsubscript{2} (PLA) releases arachidonic acid, which is converted into PGE\textsubscript{2}. This primary prostaglandin is responsible for dysmenorrhea through cooperative functions between COX-2, peroxidases (POX), and synthases. Vitamin D inhibits the expression of COX-2. As a result, arachidonic acid cannot be transformed into PGE\textsubscript{2}. Therefore it is not released from the cell membrane. This means that vitamins inhibit the de novo synthesis of arachidonic acid.\textsuperscript{35} The mechanism of action of vitamin D\textsubscript{3} is described in Figure 2.
Table 2. Dietary supplements that can complement the pharmacological treatment of PD.\(^{5,26-28}\)

<table>
<thead>
<tr>
<th>FOOD</th>
<th>FATTY ACIDS</th>
<th>MINERALS</th>
<th>VITAMINS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olive oil</td>
<td>Omega 3 and 6</td>
<td>Zinc</td>
<td>B(_1)</td>
</tr>
<tr>
<td>Turmeric</td>
<td>These fatty acids promote the formation of eicosapentaenoic and docosahexaenoic acids, and these, in turn, are less inflammatory substances such as PGE(_3), leukotrienes B(_4) and thromboxane A(_3) therefore menstruations are less painful.</td>
<td>Reduces the synthesis of prostaglandins through its endogenous antioxidant catalyst and is, in turn, an anti-inflammatory agent that improves uterine microcirculation.</td>
<td>If vitamin B(_1) deficiency is present and reversed, cramping, and fatigue decreased, and pain tolerance increased.</td>
</tr>
<tr>
<td>Dietary fiber</td>
<td>Herbal therapy relieves pain; it has been proven it reduces pain compared to pharmacological treatment. And when combined with placebo, it showed a significant pain reduction.</td>
<td>The mechanism of action has not been determined clearly, but it is believed that being a Ca(^{2+}) antagonist inhibits uterine contractility.</td>
<td>Suppresses phospholipase A(_2) and COX activity, inhibiting prostaglandin production and promoting prostacyclin with consequent vasodilation and muscle relaxation.</td>
</tr>
<tr>
<td>Fennel</td>
<td>Dietary fiber intake has an inverse correlation with the menstrual pain scale.</td>
<td>These fatty acids promote the formation of eicosapentaenoic and docosahexaenoic acids, and these, in turn, are less inflammatory substances such as PGE(_3), leukotrienes B(_4) and thromboxane A(_3) therefore menstruations are less painful.</td>
<td>Vitamin D receptors located in the uterus uptake the consumed vitamin D and inhibit prostaglandin synthesis.</td>
</tr>
<tr>
<td>Vitamin D3</td>
<td>It inhibits the effect of prostaglandins and, therefore, uterine hypercontraction. Olive oil is dose-dependent in inhibiting contractions induced with Prostaglandin PGF(_{2\alpha}) in vitro.</td>
<td>Shortens the menstrual cycle length by its action on prothrombin.</td>
<td>If vitamin B(_1) deficiency is present and reversed, cramping, and fatigue decreased, and pain tolerance increased.</td>
</tr>
</tbody>
</table>

Figure 2. Mechanism of action of Vitamin D and Zinc.\(^{35-37}\)

Vitamin D\(_3\) (cholecalciferol) has been described as more efficient than vitamin D\(_2\), the former having anti-inflammatory properties by participating in the D receptor gene (VDR), which is related to the pathogenesis of menstrual dysfunction and its consumption is associated with a 4% decrease in the risk of PD.\(^{33,38}\)

The literature describes an inverse relationship between serum levels of vitamin D and PD, thus demonstrating that vitamin D deficiency is more common in patients with dysmenorrhea due to the regulatory action of calciferol on prostaglandin levels. Studies have shown that the metabolism and absorption of vitamins and minerals may play an important role in menstrual disorders development and treatment.\(^{39}\)

That is why the intake of vitamin D3 in the form of a dietary supplement, at a dose of at least 300,000 - 500,000 IU during the luteal phase, 3 to 5 days before the menstrual phase, is recommended. This therapy should be combined with NSAIDs and complemented with Ca\(^{2+}\) supplements and has shown effectiveness in a group of Iranian female students in the clinical trial conducted by Amzajerdi et al. in 2023.\(^{40-42}\)

Vitamin D\(_3\) deficiency is understood as levels lower than 10ng/ml in serum. It results from decreased synthesis in the skin due to low sun exposure, patients with celiac disease, a history of bariatric surgery, and consumption of anticonvulsant, antiretroviral, and glucocorticoid medications. It can lead to diseases such as osteomalacia, which is the alteration of the bone matrix with an increase in unmineralized tissue: in children, it affects the cartilage growth, causing rickets. Another pathology resulting from hypovitaminosis D\(_3\) is vitamin D\(_3\) myopathy, which presents as proximal muscle weakness, alterations in hip flexion-extension and abduction, difficulty in standing up, and gait abnormalities. Other less common pathologies may include ischemic cardiovascular disease, congestive heart failure, hypertension, and autoimmune diseases.\(^{33,44}\)

On the opposite, hypervitaminosis D\(_3\) causes hypercalcemia, with serum levels >14mg/dL, which treatment is symptomatic and
requires strict control of serum calcium and vitamin D₃. It results from increased bone resorption, increased intestinal absorption, or decreased excretion.⁴⁵,⁴⁶

**Zinc**

It is the most abundant essential trace element in the human body, with its primary function being its participation in biochemical processes necessary for the cell's use of oxygen, DNA, and RNA reproduction by maintaining the integrity of the cell membrane and the elimination of free radicals, as well as protein synthesis⁴⁷,⁴⁸, and in the reproductive process, it actively participates at the level of ovulation, fertilization, and normal fetal development.⁴⁸

Zinc's daily requirement is 40mg/day. It is found in animal-derived foods, mainly lean meats from poultry, beef, and pork, as well as in seafood. Plant-based sources include nuts, seeds, and cereals.⁴⁹

The treatment of PD describes the involvement of this mineral by reducing prostaglandin synthesis through its endogenous antioxidant capacity and anti-inflammatory agent, as well as decreasing COX-2 activity, as it improves uterine microcirculation by preventing and inactivating oxygen-free radicals, thus avoiding uterine cramps. Zinc has an endogenous antioxidant effect and decreases COX-2, and the consequent production of prostaglandins.⁵⁰ Figure 2 describes Zinc’s mechanism of action.

A published study found that women who received zinc supplementation in 20-126mg/day doses for 3 to 6 days in at least three menstrual cycles reported pain intensity decrease, assessed by the Visual Analog Scale (VAS). It also found that zinc showed significant superiority over placebo, demonstrating an effective and sustained reduction in pain, where the pain intensity assessed by VAS decreased from 8-10 to 3.8 ± 2.85 over three menstrual cycles.⁵⁰,⁵¹

Supplementation with zinc is recommended at a dose of 31 mg three times a day for three days before the onset of the menstrual cycle for at least three menstrual cycles. Alternatively, long-term supplementation should be at least 15-30 mg a day, as its bioavailability is very low.⁵²,⁵³

Zinc deficiency is a result of malnutrition and, in the long term, it causes growth retardation, delayed puberty, erectile dysfunction, hypogonadism, hypochromic microcytic anemia, alterations in neurobehavioral development, skin disorders, anorexia, alterations in smell and taste, as well as impaired wound healing. Zinc overconsumption manifests as a metallic taste, abdominal cramps, vomiting, and diarrhea; toxicity presents as immune suppression, decreased HDL cholesterol, and interference with the absorption of quinolones, tetracyclines, penicillins, and thiazides.⁵⁴,⁵⁵

**CONCLUSION**

While primary dysmenorrhea (PD) has implications not only on physical but also social aspects that impact quality of life, it is our responsibility as healthcare professionals to provide the patient with the best treatment that addresses their needs. We can complement the pharmacological treatment with a supplement based on Vitamin D₃ and/or zinc since both inhibit the prostaglandins synthesis and the COX-1 and 2 syntheses, therefore, the characteristic colicky pain of PD, as long as they have certification from health authorities since quality, safety, and efficiency among the countless presentations that exist of these supplements are the main problems. While the efficacy of both supplements separately has been mentioned, we should not forget that the combination of these may vary in each patient and that no studies have been conducted using combined therapy.

This article proposes a comprehensive view of PD as it emphasizes the evidence-based importance of incorporating vitamin D₃ and zinc into pharmacological treatment. This is how dietary supplements can optimize the effectiveness of said treatment. Likewise, dosages and indications are proposed for the described supplements, which facilitates healthcare professionals in offering more effective treatments for PD, a condition normalized by society.

We must not overlook the importance of making lifestyle changes such as a low-fat diet, increased consumption of grains and seeds, fruits, vegetables, increased water intake, and engaging in at least 60 minutes of intense physical activity three times a week. These changes could even reduce the consumption of NSAIDs or eliminate PD.
REFERENCES


